ResMed Inc. (VIE:RMD)
Austria · Delayed Price · Currency is EUR | Market Cap | 26.44B -25.1% |
| Revenue (ttm) | 4.95B +9.9% |
| Net Income | 1.33B +8.8% |
| EPS | 9.13 +9.7% |
| Shares Out | n/a |
| PE Ratio | 19.83 |
| Forward PE | 17.97 |
| Dividend | 2.05 (1.05%) |
| Ex-Dividend Date | May 14, 2026 |
| Volume | n/a |
| Open | 193.90 |
| Previous Close | 192.35 |
| Day's Range | 193.90 - 195.05 |
| 52-Week Range | 159.00 - 250.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About ResMed
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring... [Read more]
Financial Performance
In fiscal year 2026, ResMed's revenue was $5.65 billion, an increase of 9.85% compared to the previous year's $5.15 billion. Earnings were $1.52 billion, an increase of 8.75%.
Financial numbers in USD Financial StatementsNews
ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat
Shares of ResMed dropped about 6% in morning trade on Friday after the medtech company forecast fiscal 2027 revenue below Wall Street expectations, impacted by suspended ventilator sales and cost pre...
ResMed price target raised to $244 from $234 at RBC Capital
RBC Capital raised the firm’s price target on ResMed (RMD) to $244 from $234 and keeps a Sector Perform rating on the shares.
ResMed price target lowered to $213 from $217 at Baird
Baird lowered the firm’s price target on ResMed (RMD) to $213 from $217 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results. Published…
ResMed price target lowered to $215 from $225 at Wells Fargo
Wells Fargo analyst Nathan Treybeck lowered the firm’s price target on ResMed (RMD) to $215 from $225 and keeps an Equal Weight rating on the shares. The firm notes the…
ResMed price target lowered to $255 from $260 at KeyBanc
KeyBanc lowered the firm’s price target on ResMed (RMD) to $255 from $260 and keeps an Overweight rating on the shares post Q4. The firm cites lower valuation multiple and…
ResMed reports Q4 EPS $2.95, consensus $2.89
Reports Q4 revenue $1.46B, consensus $1.46B. “We closed fiscal year 2026 with strong fourth quarter results, reflecting continued momentum of our global business, sustained demand for our market-leadi...
ResMed increases quarterly dividend 10% to 66c per quarter
16:27 EDT ResMed (RMD) increases quarterly dividend 10% to 66c per quarter
ResMed Earnings Call Transcript: Q4 2026
Q4 and FY 2026 saw strong revenue and EPS growth, with robust free cash flow and increased capital returns. FY 2027 guidance anticipates 5%-7% core revenue growth, margin expansion, and over $1.85 billion in shareholder returns, despite Astral-related headwinds.
ResMed Earnings release: Q4 2026
ResMed released its Q4 2026 earnings on August 6, 2026, summarizing the period's financial results.
ResMed Slides: Q4 2026
ResMed has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on August 6, 2026.
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95 Returned...
BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)
TROY, Mich., July 21, 2026 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Broadridge Financial Resources Inc. (NYSE: BR) as its "Sto...
ResMed downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded ResMed (RMD) to Sector Perform from Outperform with a price target of $234, down from $276. ResMed faces a number of challenges in FY27, including device sales…
ResMed price target lowered to $220 from $235 at Mizuho
Mizuho lowered the firm’s price target on ResMed (RMD) to $220 from $235 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical device and…
ResMed downgraded to Neutral from Buy at Citi
Citi analyst Laura Sutcliffe downgraded ResMed (RMD) to Neutral from Buy with a price target of $235, down from $270. The firm sees the company’s earnings growth dropping in fiscal…
ResMed price target lowered to $225 from $240 at Jefferies
Jefferies lowered the firm’s price target on ResMed (RMD) to $225 from $240 and keeps a Hold rating on the shares. Recent developments at ResMed, including the MatrixCare divestiture, Noctrix…
ResMed price target lowered to $276 from $321 at RBC Capital
RBC Capital lowered the firm’s price target on ResMed (RMD) to $276 from $321 and keeps an Outperform rating on the shares to reflect the company having announced the sale…
ResMed price target lowered to $225 from $227 at Wells Fargo
Wells Fargo lowered the firm’s price target on ResMed (RMD) to $225 from $227 and keeps an Equal Weight rating on the shares. The company announced the sale of MatrixCare,…
ResMed to sell software business MatrixCare for $490 million
ResMed said on Tuesday it would sell its software business MatrixCare to private equity firm Frazier Healthcare Partners for $490 million in cash, as the health technology company sharpens its focus...
Frazier to acquire MatrixCare from ResMed, terms not disclosed
Frazier Healthcare Partners, a private equity firm focused exclusively on the healthcare industry, announced it has entered into a definitive agreement to acquire MatrixCare from ResMed (RMD). “Frazie...
Frazier Healthcare Partners Announces Definitive Agreement to Acquire MatrixCare
SEATTLE--(BUSINESS WIRE)--Frazier Healthcare Partners ("Frazier"), a private equity firm focused exclusively on the healthcare industry, today announced it has entered into a definitive agreement to a...
ResMed to sell MatrixCare business to Frazier Healthcare, terms undisclosed
Resmed (RMD) announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners. The transaction includes MatrixCare and related software offerings his...
Resmed Announces Agreement to Sell MatrixCare Business
SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has ente...
ResMed Slides: Divestiture of MatrixCare presentation
ResMed has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
ResMed added to APAC Conviction List at Goldman Sachs
Goldman Sachs analysts added ResMed (RMD) to the firm’s APAC Conviction List as part of its monthly update. The firm expects continuous airway pressure therapy patient growth for the company.